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Background. VCL-CB01, a candidate cytomegalovirus (CMV) DNA vaccine that contains plasmids encoding
CMV phosphoprotein 65 (pp65) and glycoprotein B (gB) to induce cellular and humoral immune responses and that
is formulated with poloxamer CRL1005 and benzalkonium chloride to enhance immune responses, was evaluated in
a phase 1 clinical trial.
Methods. VCL-CB01 was evaluated in 44 healthy adult subjects (22 CMV seronegative and 22 CMV seropositive)
18 – 43 years old. Thirty-two subjects received 1- or 5-mg doses of vaccine on a 0-, 2-, and 8-week schedule, and 12
subjects received 5-mg doses of vaccine on a 0-, 3-, 7-, and 28-day schedule.
Results. Overall, the vaccine was well tolerated, with no serious adverse events. Local reactions included mild to
moderate injection site pain and tenderness, induration, and erythema. Systemic reactions included mild to moderate
malaise and myalgia. All reactions resolved without sequelae. Through week 16 of the study, immunogenicity, as
measured by enzyme-linked immunosorbant assay and/or ex vivo interferon (IFN)– enzyme-linked immunospot
assay, was documented in 45.5% of CMV-seronegative subjects and in 25.0% of CMV-seropositive subjects who
received the full vaccine series, and 68.1% of CMV-seronegative subjects had memory IFN- T cell responses at
week 32.
Conclusion. The safety and immunogenicity data from this trial support further evaluation of VCL-CB01.
Cytomegalovirus (CMV), a betaherpesvirus, infects
50%– 85% of adults by 40 years of age [1]. Most healthy
individuals who acquire CMV after birth develop few, if
any, symptoms; however, CMV disease causes signifi-
cant morbidity and mortality in immunocompromised
individuals, such as recipients of hematopoietic cell
transplants (HCT) and solid-organ transplants [2]. In
HIV-infected individuals, CMV infection accelerates
progression to AIDS and death, despite antiretroviral
therapy [3]. In the United States, congenital abnormal-
ities due to transplacental infection with CMV lead to
death or birth defects, including deafness and mental
retardation, in 8000 infants each year [4, 5]. A CMV
vaccine is currently not available, even though the Insti-
tute of Medicine ranked CMV as the top priority for
vaccine development in the United States [6].
The incidence of CMV antigenemia in CMV-
seropositive HCT recipients who do not receive prophy-
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laxis is 50%–70% during the first 100 days after transplant [7, 8].
Preemptive antiviral therapy reduces the incidence of CMV-
associated disease to 5% [9]; however, drug toxicity, the ex-
pense of antiviral treatment, and the possibility of the emergence
of drug-resistant viruses are major drawbacks to the use of anti-
virals for prevention of CMV disease. Even with antiviral ther-
apy, patients may develop viremia, or they may develop “late-
onset” CMV viremia and disease after the therapy is
discontinued [10, 11]. A CMV vaccine that enables the patient’s
immune system to control CMV infection, resulting in a reduced
need for antiviral therapy, would be a valuable therapeutic op-
tion for HCT recipients.
Control of CMV in immunocompromised persons is primar-
ily associated with cellular immune responses. Both CD8 and
CD4T cells appear to be important for protection against CMV
disease [12, 13]. A recent study of CMV-specific CD4 and
CD8 T cells from healthy donors used overlapping peptides
from 213 CMV open reading frames to identify antigens recog-
nized after CMV infection [14]. The CMV tegument phospho-
protein 65 (pp65) and the major CMV surface glycoprotein B
(gB) were the antigens most frequently recognized by CD4 T
cells, and pp65 was also one of the antigens most frequently
recognized by CD8 T cells.
The development of a vaccine for the prevention of congenital
infection by transplacental transmission of CMV is also a high
priority. In contrast to the transplant setting, antibodies to sur-
face glycoproteins, especially gB, appear to be critical for protec-
tion against the maternal-fetal transfer of CMV [15]. In addi-
tion, CMV-specific T cell responses are also likely to play an
important role in reducing viral load in the mother and, thus,
exposure of the fetus.
A CMV vaccine that induces protective T cell and antibody
responses has the potential to prevent infection or ameliorate
CMV disease due to congenital infection or transplantation. To
that end, we developed a CMV DNA vaccine, VCL-CB01, com-
posed of two plasmids with human codon-optimized CMV
genes, pp65 and gB [16]. CMV pp65 was included to induce T
cell responses; gB was included to induce antibodies and T cell
responses. VCL-CB01 was formulated with poloxamer CRL1005
and benzalkonium chloride (BAK) to increase immunogenicity.
MATERIALS AND METHODS
VCL-CB01 vaccine. VCL-CB01, a bivalent CMV DNA vac-
cine consisting of 2 plasmids, VCL-6368 and VCL-6365, formu-
lated with poloxamer CRL1005 and BAK in PBS, has been de-
scribed elsewhere [16]. VCL-6368 encodes pp65 from AD169
with the putative protein kinase domain removed by deletion of
aa 435– 438. VCL-6365 encodes the extracellular domain (aa
1–713) of CMV gB. Formulation of the 2 plasmids with
CRL1005 and BAK produces a thermodynamically stable, self-
assembled particulate system with a defined particle size, surface
charge, and stability profile.
Trial design. VCL-CB01 was evaluated for safety and im-
munogenicity in a phase 1, multicenter, open-label, dose-
escalating trial in healthy CMV-seropositive and CMV-
seronegative adults. Subjects received intramuscular (deltoid)
injections of 1- or 5-mg doses of VCL-CB01 on a 0-, 2-, and
8-week schedule (groups 1 and 2, respectively) or 5-mg doses of
VCL-CB01 on a 0-, 3-, 7-, and 28-day schedule (group 3). Blood
was collected for assessment of immune responses at baseline
and weeks 2, 4, 8, 10, 16, 24, and 32 for groups 1 and 2 and at
baseline and weeks 1, 2, 4, 6, 12, and 16 for group 3. The end
points of the trial were safety and immunogenicity, as defined by
gB antibody responses measured by ELISA and pp65 interferon
(IFN)– T cell responses measured by ex vivo enzyme-linked
immunospot (ELISPOT) assay. An additional assay, the cul-
tured IFN-ELISPOT assay, was used to further evaluate immu-
nogenicity.
An institutional review board approved the clinical protocol
and informed consent at each of 4 sites, and written informed
consent was obtained at enrollment from each volunteer before
any procedures were conducted.
Safety assessment. Safety was assessed by measurement of
vital signs, laboratory tests, review of reactogenicity 30 min after
each injection, symptom-directed clinical evaluations, postin-
jection subject diaries, adverse event (AE) monitoring, and re-
Table 1. Subject distribution.
Group
Injection
schedule
Dose per
injection, mg
CMV-seropositive
subjects
CMV-seronegative
subjects
1 Week 0, 2, 8 1 8a 8b
2 Week 0, 2, 8 5 8c 8
3 Day 0, 3, 7, 28 5 6 6
Total 22 22
NOTE. CMV, cytomegalovirus.
a One subject, who received only a single injection, discontinued the trial after week 2; a
second subject, who received all 3 injections, discontinued the trial after week 10.
b One subject, who received all 3 injections, discontinued the trial after week 24.
c One subject, who received only 2 injections, discontinued the trial after week 2.
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view of concomitant medication usage. Toxicity tables and
grades established by the National Institute of Allergy and Infec-
tious Diseases were used for evaluating AEs.
Ex vivo ELISPOT assay. Peripheral blood mononuclear
cells (PBMCs) isolated from blood shipped overnight from the
study sites were cryopreserved after each blood collection. The
ex vivo ELISPOT assay for detection of IFN-–secreting T cells
was developed and qualified at the Vical Clinical Immunoassay
Laboratory. The assay was performed with thawed PBMCs ob-
tained at multiple time points, including baseline, in the same
plate. In our experience, cryopreservation of PBMCs for1 year
does not reduce responses relative to fresh PBMCs in the ex vivo
ELISPOT assay (authors’ unpublished data); moreover, the use
of cryopreserved PBMCs allows batching of PBMCs from vari-
ous time points in a single assay to minimize the effects of assay
variability.
For the ex vivo ELISPOT assay, PBMCs at 200,000 cells/well in
96-well plates were stimulated overnight at 37°C in 5% CO2 with
pools of overlapping 15mer peptides (Biosynthesis). CMV pp65
and gB peptides, derived from sequences of antigens encoded in
VCL-CB01, either were in a single pool of 137 or 176 peptides,
respectively, at 7.5 g/mL for each peptide or were split into 2
pools at 10g/mL for each peptide. Wells were coated with anti–
human IFN- antibody (BD Pharmingen) and were developed
by sequential addition of biotinylated anti– human IFN- anti-
body (BD Pharmingen), avidin-horseradish peroxidase (HRP)
(Vector Laboratories), and 3-amino-9-ethylcarbazole (AEC)
substrate (BD Pharmingen). Spot-forming units were counted
with an ImmunoSpot Analyzer (CTL). Results were expressed as
the number of spot-forming units per 1  106 PBMCs after sub-
traction of the number of spot-forming units in wells without
peptides. Controls included phytohemagglutinin (PHA)–stim-
ulated PBMCs, wells without peptide, a pool of 98 overlapping
peptides derived from CMV immediate-early antigen 1 (IE1)
(which is not encoded in VCL-CB01), and control PBMCs with
established ranges for pp65, IE1, and gB.
Cultured ELISPOT assay. PBMCs were seeded at 2  106
cells/well in 24-well plates and cultured for 10 days at 37°C in 5%
Table 2. Maximum toxicity grade (MTG) of related adverse events (AEs), by treatment group.
AE
Group 1
MTG
(n  16)
Group 2
MTG
(n  16)
Group 3
MTG
(n  12)
Totala1 2 3 1 2 3 1 2 3
General disorders and administration
site conditions
Injection site pain 7 2 1 10 4 0 4 8 0 36 (81.8)
Malaise 4 1 0 5 1 0 5 2 0 18 (40.9)
Feeling hot and cold 1 1 0 3 0 0 0 0 0 5 (11.4)
Injection site induration 0 0 0 3 0 0 2 0 0 5 (11.4)
Fatigue 1 2 0 0 0 0 0 0 0 3 (6.8)
Injection site erythema 0 0 0 1 0 0 2 0 0 3 (6.8)
Injection site pruritis 1 0 0 1 0 0 1 0 0 3 (6.8)
Pyrexia 0 0 0 3 0 0 0 0 0 3 (6.8)
Feeling hot 1 1 0 0 0 0 0 0 0 2 (4.5)
Injection site swelling 0 0 0 0 0 0 2 0 0 2 (4.5)
Rigors 0 0 0 1 0 0 1 0 0 2 (4.5)
Musculoskeletal and connective tissue
Myalgia 3 3 0 8 3 0 6 1 0 24 (54.5)
Nervous system
Headache 5 1 0 7 0 0 5 0 0 18 (40.9)
Gastrointestinal
Nausea 0 0 0 3 0 0 0 0 0 3 (6.8)
Skin and subcutaneous tissue disorders
Erythema 0 0 0 2 0 0 0 0 0 2 (4.5)
Pruritis 0 1 0 1 0 0 0 0 0 2 (4.5)
Rash 1 0 0 0 0 0 1 0 0 2 (4.5)
Investigations
Decrease in Hb level 1 0 0 1 0 0 0 0 0 2 (4.5)
NOTE. No toxicity grade 4–related AEs were reported. Subjects may have had 1 occurrence of the same event;
however, only 1 occurrence was counted per subject. Hb, hemoglobin.
a Data are the no. (%) of subjects with a related AE from among the total no. of subjects (n  44).
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CO2 with overlapping peptides (described above) at 0.2 g/mL
for each peptide. Separate wells were cultured with pp65, gB, or
IE1 peptides. Recombinant human interleukin (IL)–2 (eBio-
science) at 900 U/mL was added on days 3 and 7. After 10 days,
cells were washed and rested overnight in medium without pep-
tides. The IFN- ELISPOT assay was performed as described
above except that cells were plated at 40,000 cells/well. Data were
expressed as the number of spot-forming units per 1  106 cul-
tured cells after subtraction of the number of spot-forming units
in wells without peptide. Controls included wells without pep-
tide, wells with IE1 peptides, and control PBMCs cultured in the
same manner as the test samples.
CMV gB antibody ELISA. Serum gB-specific IgG antibod-
ies were detected in a gB-binding ELISA developed and qualified
at the Vical Clinical Immunoassay Laboratory. The assay uses
96-well plates coated with 2 g/mL recombinant gB purified
from stably transfected CHO cells (gift from Sanofi-Aventis).
Serum specimens were screened for gB binding at 1:100 and, if
positive, serial dilutions of the serum were assayed with a refer-
ence serum to determine anti-gB antibody levels in ELISA units
(EU) per milliliter. Antibody binding was detected with an HRP-
conjugated goat anti– human IgG Fc antibody (Jackson Immu-
noResearch), followed by ABTS substrate (KPL) and stop solu-
tion (KPL). Absorbance was read at 405 nm with a reference at
490 nm, and gB antibody levels were interpolated from a stan-
dard curve. Controls in the assay included positive and negative
serum specimens with established ranges for EU per milliliter
and reagent control wells.
Statistical analyses. The primary analysis was the inci-
dence of AEs. Descriptive summary statistics for continuous
variables, including the mean, SD, median, minimum, and
maximum, were used to summarize safety data. Summa-
ries for categorical variables were presented as counts and
percentages. Fisher’s exact test was used to test for significant
group differences.
RESULTS
Trial subjects. A total of 44 subjects (22 CMV seropositive and
22 CMV seronegative) were enrolled, including 18 men (40.9%)
and 26 women (59.1%) (table 1). The race characteristics of the
subject population were as follows: 37 white (84.1%), 3 African
American (6.8%), 1 Asian (2.3%), and 3 other/unknown (6.8%).
Seven subjects (15.9%) were Hispanic or Latino, and 37 (84.1%)
were not. The mean age of the subjects was 28.6 years and ranged
from 18 to 43 years. Four subjects discontinued the study; 2
discontinued before receiving the third dose of vaccine, and 2
discontinued after receiving all of the vaccine doses. No subject
discontinued due to vaccine-related AEs.
Safety. In general, VCL-CB01 was well tolerated. No serious
AEs were reported. The most common vaccine-related AEs con-
sisted of injection site pain (81.8%), myalgia (54.5%), headache
(40.9%), and malaise (40.9%). AEs were generally of mild to
moderate severity. Thirty-six subjects (81.8%) experienced at
least 1 related grade 1 AE. Eighteen subjects (40.9%) developed
at least 1 related grade 2 AE. One related grade 3 AE (pain at the
injection site) was experienced by 1 subject after the second
1-mg injection (day 14), which abated to a grade 2 level within 1
day and resolved within 10 days. There were no grade 4 AEs. The
maximum toxicity grades of related AEs, sorted by treatment
group, are shown in table 2. The duration of the most commonly
reported related AEs ranged from 1 to 4 days, with the exception
of 1 grade 2 AE (feeling hot or cold) in 1 subject, with a duration
of 7 days.
Group 2 and 3 subjects generally experienced more local re-
actogenicity than did group 1 subjects. In particular, there was
more injection site pain with the higher dose (group 2, 87.5%)
and accelerated schedule (group 3, 100%) versus group 1
(62.5%). Similarly, only subjects in groups 2 and 3 experienced
injection site erythema (6.2% and 16.7%, respectively) and in-
jection site induration (18.8% and 16.7%, respectively). Injec-
tion site swelling was reported for subjects in group 3 only
Table 3. Vaccine responders, by group and cytomegalovirus (CMV) serostatus.
Response
Group 1 Group 2 Group 3
SN (n  8) SP (n  8) SN (n  8) SP (n  8) SN (n  6) SP (n  6)
gB antibody 2 (25.0) 0 (0) 2 (25.0) 0 (0) 1 (16.7) 0 (0)
pp65 ex vivo IFN- ELISPOT 2 (25.0) 3 (37.5) 3 (37.5) 1 (12.5) 3 (50.0) 1 (16.7)
gB ex vivo IFN- ELISPOT ND ND 2 (25.0) ND 2 (33.3) ND
Total 3 (37.5) 3 (37.5) 4 (50.0) 1 (12.5) 3 (50.0) 1 (16.7)
NOTE. Data are no. (%) of subjects. Vaccine responders were defined as those with a vaccine-induced antibody or T cell response
before or at week 16 (day 112). Antibody responders to the CMV glycoprotein B (gB) were defined as those who had serum specimens
that were negative by the gB ELISA before vaccination and that were positive by the assay after vaccination or those who had serum
specimens that were positive by the assay at baseline and had a postvaccination increase in gB antibody level of 4-fold relative to
baseline. Ex vivo interferon (IFN)– enzyme-linked immunospot (ELISPOT) assay responders to the CMV phosphoprotein 65 (pp65) or gB
were defined as those with negative results by the ex vivo IFN- ELISPOT assay before vaccination and positive results by the assay after
vaccination or those with positive results by the ex vivo IFN- ELISPOT assay before vaccination and a postvaccination increase in the level
of pp65-specific IFN-–secreting T cells of 2.4-fold. ND, not done; SN, seronegative; SP, seropositive.
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(16.7%). Dose and injection schedule had no consistent rela-
tionship to the frequency of systemic symptoms. In addition, the
onset of the immunogenic response did not correlate with an
increase in the number of local or systemic AEs.
Immunogenicity. The immunogenicity of VCL-CB01 was
initially assessed through week 16 by the pp65 ex vivo ELISPOT
assay for T cell responses and at all time points by gB-binding
ELISA for antibody responses. In addition, gB T cell responses
were assessed for CMV-seronegative subjects in group 2 at week
10 and in group 3 at week 12 by the IFN- ELISPOT assay. As
indicated in table 3, CMV-seronegative subjects in all groups
had vaccine-induced pp65 and/or gB T cell responses (25.0%–
50.0%) and gB antibody responses (16.7%–25.0%). The gB an-
tibody responses detected with the gB ELISA were not likely to
have been induced as a result of CMV infection during the
course of the trial, because all CMV-seronegative subjects were
negative by CMV ELISA (Diamedix CMV IgG and IgM ELISA)
at the last time point in the trial (authors’ unpublished data).
CMV-seropositive subjects in all groups had vaccine-induced
increases in pp65-specific T cells (range, 12.5%–37.5%), but, for
CMV-seropositive subjects in any group, gB antibody levels did
not increase2-fold over baseline after vaccination.
Immune response kinetics. Individual results and time
courses for T cell and antibody responses through week 16 for
CMV-seronegative subjects are shown in figures 1 and 2. In gen-
eral, relative to the initial injection, T cell responses peaked by
weeks 10 –12 and antibody responses peaked by weeks 12–16.
The kinetics of the responses relative to the first injection appear
to be similar for both injection schedules.
Priming of memory T cells. To more fully evaluate the
ability of VCL-CB01 to prime for memory T cell responses, we
assayed PBMCs from week 32 for CMV-seronegative subjects in
groups 1 and 2 by the ex vivo ELISPOT assay. In addition,
PBMCs from week 32 for CMV-seronegative subjects in groups
Figure 1. T cell responses for cytomegalovirus (CMV)–seronegative subjects. Ex vivo interferon (IFN)– enzyme-linked immunospot (ELISPOT) assays
were performed as described in Materials and Methods. Individual CMV phosphoprotein 65 (pp65) T cell responses are shown for CMV-seronegative
subjects vaccinated with 1-mg (A) or 5-mg (B) doses of VCL-CB01 at 0, 2, and 8 weeks and for CMV-seronegative subjects with 5-mg doses of VCL-CB01
at 0, 3, 7, and 28 days (C). ELISPOT results are shown as the no. of spot-forming units per 1  106 peripheral blood mononuclear cells (PBMCs).
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1 and 2 and from week 16 for group 3 were evaluated by the
cultured ELISPOT assay, which may be more sensitive for assess-
ing DNA vaccine priming of memory responses. Distinct from
the ex-vivo ELISPOT assay, in which PBMCs are cultured over-
night with peptides, the cultured ELISPOT assay involves cultur-
ing PBMCs with peptides and recombinant human IL-2 for 10
days before use in the IFN- ELISPOT assay. Thus, the cultured
ELISPOT assay detects antigen-specific T cells with the capacity
to proliferate and secrete IFN- on restimulation with antigen
[17].
As indicated in table 4, antigen-specific pp65 or gB IFN- T
cell responses were detected by ex vivo and/or cultured ELISPOT
assay in 15 (68.1%) of 22 CMV-seronegative subjects up to 24
weeks after the last injection. No memory T cell responses were
detected after culture with the IE1-specificity control peptides
and IL-2.
Group 1 responders who were initially identified by the ex
vivo ELISPOT assay at earlier time points failed to demonstrate
responses by the same ex vivo assay by week 32. All subjects in
group 2 who had T cell responses by week 16 by the ex vivo
ELISPOT assay also had detectable responses by the same assay
at week 32. Interestingly, 2 additional subjects in group 2
(V01OC021 and V01OC022) had detectable pp65 and/or gB re-
sponses by the ex vivo ELISPOT assay at week 32 even though T
cell responses had not been previously detected in PBMCs from
those subjects through week 16. Two of 3 responders in group 3
had a detectable pp65 T cell responses by the ex vivo ELISPOT
assay at week 16.
DNA vaccine–induced memory T cell responses were de-
tected by the cultured ELISPOT assay in PBMCs from 6 subjects
in group 1 (75.0%), 5 subjects in group 2 (62.5%), and 4 subjects
in group 3 (66.7%). Furthermore, memory T cell responses were
detected in 5 subjects (4 in group 1 and 1 in group 3) who failed
to demonstrate a T cell response by the ex vivo ELISPOT assay at
any time point. Thus, the cultured ELISPOT assay appears to be
more sensitive than the ex-vivo ELISPOT assay for detection of
vaccine-induced antigen-specific T cell responses.
DISCUSSION
The results from this trial show that VCL-CB01, a bivalent CMV
DNA vaccine, was generally well tolerated and that the severity of
AEs did not increase significantly with increasing dose or with
an accelerated vaccination schedule. Through week 16 of
the study, immunogenicity, as measured by ELISA and/or ex
vivo ELISPOT assay, was documented in 45.5% of CMV-
seronegative subjects and 25.0% of CMV-seropositive subjects
who received the full vaccine series. Two additional subjects had
detectable IFN- T cell responses only at week 32, and 68.1% of
subjects had memory IFN- T cell responses. In CMV-
seropositive subjects, VCL-CB01 boosted existing pp65 T cell
responses but not gB antibody responses, possibly because of the
high baseline levels of gB antibody in subjects with chronic CMV
infection.
Figure 2. Antibody responses for cytomegalovirus (CMV)–seronegative
subjects. CMV glycoprotein B (gB) ELISAs were performed as described in
Materials and Methods. A serum specimen was considered to be positive if
the absorbance for serum at a 1:100 dilution was greater than a reactivity
threshold calculated as 2.5 times the absorbance of pooled CMV-
seronegative serum specimens at a 1:100 dilution. Anti-gB levels (shown in
ELISA units [EU] per milliliter) were interpolated from a standard curve using
serum with well-defined reactivity to CMV gB. In a survey of 76 CMV-
seronegative serum specimens and 55 CMV-seropositive serum specimens,
the assay had a sensitivity of 100% and specificity of 95%. The results for
the CMV-seropositive serum specimens ranged from 16,350 to 413,440
EU/mL, with a median value of 154,560 EU/mL (authors’ unpublished data).
Individual gB antibody responses are shown for CMV-seronegative subjects
vaccinated with 1-mg (A) or 5-mg (B) doses of VCL-CB01 at 0, 2, and 8 weeks
and for CMV-seronegative subjects vaccinated with 5-mg doses of VCL-CB01
at 0, 3, 7, and 28 days (C).
Phase 1 Trial of a CMV DNA Vaccine ● JID 2008:197 (15 June) ● 1639
Table 4. Ex vivo and cultured interferon (IFN)– enzyme-linked immunospot (ELISPOT) assay responses
for cytomegalovirus (CMV)–seronegative subjects.
Group, subject
Ex vivo ELISPOT
assay results,
sfu/106 PBMCsa
Cultured IFN- ELISPOT assay results,
sfu/106 cultured cellsb
pp65 gB IE1 pp65 gB IE1
Week 32 Week 0 Week 32 Week 0 Week 32 Week 0 Week 32
Group 1
V01OC002 0 0 0 100 242 6 1475 75 14
V01OC005 8 10 12 0 42 50 83 42 25
V01OC008c 3 3 8 36 792 0 92 17 183
V01OC009 3 1 8 0 6 50 6 250 192
V01OC013 18 29 1 125 2258 92 125 0 42
V01OC014 29 31 4 11 1967 50 4467 0 0
V01OC016 32 22 8 11 2417 47 783 14 100
V01ST001 12 23 17 6 358 217 608 75 89
Group 2
V01ST002 0 3 0 11 0 8 33 0 0
V01ST004 52 25 15 75 5017 56 775 14 58
V01CO001 3 9 7 17 39 53 117 36 0
V01FH001 70 40 2 33 2433 6 542 50 17
V01OC021d 90 92 25 100 6067 217 5575 111 150
V01ST005 0 3 6 0 0 8 14 17 17
V01FH004 96 33 27 61 417 8 6375 19 33
V01OC022 27 53 0 3 4517 383 1600 42 50
Week 16e Week 0 Week 16 Week 0 Week 16 Week 0 Week 16
Group 3
V01OC023 14 ND 0 33 58 333 538 8 11
V01OC026 56 ND 0 28 1900 542 1658 19 17
V01OC029 78 ND 0 53 1267 0 792 67 50
V01FH005 5 ND 5 17 1542 58 2100 25 108
V01OC030 8 ND 5 8 0 0 3 0 6
V01ST006 8 ND 0 11 583 17 950 33 92
a A subject was considered to be a responder to the cytomegalovirus (CMV) proteins phosphoprotein 65 (pp65), glycoprotein
B (gB), or immediate-early antigen 1 (IE1) by ex vivo interferon (IFN)– enzyme-linked immunospot (ELISPOT) assay if the mean
no. of spot-forming units per 1  106 peripheral blood mononuclear cells (PBMCs) for replicate wells was 50 and the mean no.
of spot-forming units per well for replicate wells was greater than twice the mean background (without peptide) level. Positive
responses are shown in boldface type. By use of the established cutoff in assay qualification studies, 63 CMV-seronegative
subjects were negative by the assay (100% specificity), and 50 CMV-seropositive subjects were positive for at least 1 of the 3
antigens by the assay (100% sensitivity); positive responses for the CMV-seropositive subjects ranged from 50 sfu/1  106
PBMCs to the upper limit of the assay, 6000 sfu/1  106 PBMCs (authors’ unpublished data).
b A subject was considered to be a responder to pp65, gB, or IE1 by the cultured ELISPOT assay if the no. of spot-forming
units per 1  106 cultured cells was 250 and the no. of spot-forming units per well was 2 times that in wells without peptide.
Data from the analysis of PBMCs from CMV-seronegative subjects before administration of the CMV DNA vaccine suggested
that some subjects may have had low levels of cross-reactive T cell responses to peptides in the pools (data not shown);
therefore, the criteria for a positive response to the vaccine included the requirement that the no. of spot-forming units per
1  106 cultured cells was 2 times that at baseline. Positive responses are shown in boldface type. By use of these criteria,
no positive responses were detected for PBMCs stimulated with the IE1-specificity control peptides (IE1 is not encoded in the
vaccine; for CMV-seronegative subjects vaccinated with VCL-CB01, n  22; specificity for the vaccine response was 100%). The
lack of IE1 responses in PBMCs from CMV-seronegative subjects up to week 32 of the study suggests that none of these
subjects acquired CMV during the course of the trial.
c Week 0 PBMCs were not available; week 2 PBMCs were used in the assay.
d Week 32 PBMCs were not available; week 24 PBMCs were used in the assay.
e Results from the initial evaluation by the ex vivo ELISPOT assay in which pp65 peptides were split into 2 pools each are
reported. The data are the sums of the no. of spot-forming units per 1  106 PBMCs for pool I and pool II.
The protracted time to peak responses was unexpected and
may be related to the mechanism of action for DNA vaccines,
which is likely to differ from that of conventional vaccines. In
theory, in humans DNA vaccines produce low levels of im-
munogen for extended periods of time after vaccination [18]. In
the absence of a large bolus of antigen, the immune response
may not produce large effector responses but could prime
antigen-specific memory cells. Indeed, DNA vaccines are used
for the priming doses of several heterologous prime-boost vac-
cine regimens currently being evaluated in humans for the pre-
vention of HIV infection and malaria [19, 20, 21]. With those
vaccines, immune responses primed with DNA vaccine– encod-
ing pathogen-derived proteins are boosted to higher levels with a
viral-vectored vaccine encoding the same proteins. In a similar
way, a CMV DNA vaccine could prime for a memory response
that is boosted on exposure to CMV during a primary infection
or on reactivation, resulting in rapid control of the virus and
protection against CMV-associated disease.
Assays that measure only effector cell function directly ex vivo
may not be adequate for detecting the priming of immune re-
sponses by DNA vaccines or for assessing the potential for
mounting a memory response on exposure to the pathogen tar-
geted by the vaccine. The results from our cultured ELISPOT
assay suggest that induction of a directly measurable effector
response is not required for priming of antigen-specific memory
T cells. In fact, memory T cell responses were detected in 5 sub-
jects who failed to demonstrate responses by the ex vivo
ELISPOT assay at any time point. Establishment of the cultured
ELISPOT assay as a correlate of DNA vaccine priming of im-
mune memory will require evaluation of the assay in the context
of a trial in which a memory response could be measured. For
example, administration of the live attenuated CMV Towne
strain vaccine strain) to CMV DNA vaccinated subjects, while
not strictly a pathogenic challenge, could be used to demonstrate
CMV antigen–specific T cell and B cell memory responses to
CMV infection. The administration of Towne strain vaccine was
previously used to demonstrate antibody priming by a canary-
pox virus vaccine encoding CMV gB; antibody responses after
the administration of Towne strain vaccine occurred earlier and
were of higher magnitude than those induced in subjects who
were not primed with the CMV gB canarypox virus vaccine [22].
A correlation between cultured ELISPOT responses before ad-
ministration of Towne strain vaccine to subjects vaccinated with
a CMV DNA vaccine and a memory T cell response to the same
antigens after administration of Towne strain vaccine would
support the use of the cultured ELISPOT assay for evaluation of
the priming of memory immune responses induced by DNA
vaccines.
The CMV DNA vaccine evaluated here was more effective for
inducing CMV antigen–specific T cells than gB-specific anti-
body. The likelihood of success for a CMV DNA vaccine focused
primarily on the induction of cellular immune responses in the
transplant population is supported by several investigations.
First, disease severity after allogeneic transplants was decreased
by infusing transplant recipients with CMV-specific T cells ex-
panded ex vivo from the donors [13, 23, 24]. Second, a live at-
tenuated vaccine (Towne strain) was used to ameliorate disease
severity in CMV-seronegative renal transplant recipients who
had received an organ from a CMV-seropositive donor [25]. In
these studies, the emphasis was on the prevention of disease
rather than infection. Last, strong inverse correlations between
the magnitude of both CD4 and CD8 T cell responses and the
development of disease in transplant recipients have been re-
ported [12, 26].
Unlike in the transplant setting, antibody responses directed
to the major surface glycoproteins, especially gB, appear to be
critical in preventing maternal-fetal transmission, but antibody
responses do not provide complete protection against maternal-
fetal transmission of CMV [15]. Infection with other CMV ge-
notypes or reactivation of latent CMV infection can occur with
subsequent transplacental transmission to the fetus. Cell-
mediated immune responses to CMV immunogens, such as
pp65, are also likely to play an important role in reducing the
maternal viral load, which could reduce maternal-fetal transmis-
sion or the occurrence of disease.
The potential efficacy of a plasmid-based vaccine approach to
the prevention of maternal-fetal transmission was recently dem-
onstrated in a guinea pig model of transplacental transmission of
guinea pig CMV (GPCMV). Administration of a DNA vaccine
encoding the GPCMV gB before conception induced gB anti-
body responses and decreased viral loads in live-born guinea pig
pups of vaccinated dams challenged with GPCMV during preg-
nancy [27]. A more recent study using an alphavirus replicon
vaccine encoding the GPCMV homologue of pp65 in the guinea
pig model indicated that T cell responses to pp65 correlated with
a reduction in viral load in the peripheral blood of the dams and
a reduction in pup mortality [28]. Thus, the results in the guinea
pig model suggest that DNA vaccine–induced antibody and cell-
mediated immune responses could reduce CMV infection and
disease.
A vaccine against CMV is currently not available; however,
live attenuated CMV vaccines, canarypox-vectored vaccines,
and recombinant gB protein vaccines have been or are currently
in clinical trials [29]. The use of a CMV DNA vaccine in immu-
nocompromised subjects would eliminate the safety concerns of
live attenuated CMV or live recombinant viral-vectored vac-
cines. In addition, a CMV DNA vaccine has the advantage of
delivering CMV antigens while avoiding the many CMV-
encoded products involved in immune evasion [30].
In summary, the results of this phase 1 clinical trial suggest
that VCL-CB01, a bivalent CMV DNA vaccine, was well toler-
ated and immunogenic. The vaccine induced both gB antibodies
and T cell responses to both pp65 and gB at a 1- or 5-mg dose on
either injection schedule and the priming of memory T cells in a
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majority of CMV-seronegative subjects. The safety and immu-
nogenicity data from this trial support further clinical investiga-
tion of VCL-CB01.
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